Find the right fit for you - faster
Get tailored insights about working at Amunix in one quick step.
Amunix Snapshot
Safely Harnessing the Immune System to Conquer Cancer
At Amunix, we are focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. We are leveraging our proprietary T cell engager (XPAT) and cytokine (XPAC) platforms to advance novel prodrugs that overcome the toxicity and immunogenicity challenges common to these therapeutic modalities via selective activation in the tumor microenvironment. By delivering breakthrough therapies that can safely harness the immune system, we aim to conquer cancer and save lives.
Since our founding in 2006, we have operated as a technology licensing company, forging agreements with multiple leading biopharmaceutical companies such as Roche, Merck, Celgene, and Biogen, to leverage XTEN, a proprietary half-life extension technology, and Pro-XTEN, a next-generation prodrug technology. Pro-XTEN utilizes a protease-releasable XTEN polypeptide as a mask, thus enabling localized activation of potent therapies. This technology is designed to overcome a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Pro-XTEN, which is the foundational technology for the XPAT and XPAC platforms, has been clinically validated, with the most advanced program utilizing the technology currently in a pivotal Phase 3 study for a non-oncology indication.
We are advancing our lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and we have several discovery programs underway
Since our founding in 2006, we have operated as a technology licensing company, forging agreements with multiple leading biopharmaceutical companies such as Roche, Merck, Celgene, and Biogen, to leverage XTEN, a proprietary half-life extension technology, and Pro-XTEN, a next-generation prodrug technology. Pro-XTEN utilizes a protease-releasable XTEN polypeptide as a mask, thus enabling localized activation of potent therapies. This technology is designed to overcome a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Pro-XTEN, which is the foundational technology for the XPAT and XPAC platforms, has been clinically validated, with the most advanced program utilizing the technology currently in a pivotal Phase 3 study for a non-oncology indication.
We are advancing our lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and we have several discovery programs underway
